William A. Hall

ORCID: 0000-0001-7017-6755
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic and Hepatic Oncology Research
  • Advanced Radiotherapy Techniques
  • Radiomics and Machine Learning in Medical Imaging
  • Prostate Cancer Diagnosis and Treatment
  • Prostate Cancer Treatment and Research
  • Cancer Genomics and Diagnostics
  • Medical Imaging Techniques and Applications
  • Renal cell carcinoma treatment
  • Radiation Therapy and Dosimetry
  • Colorectal Cancer Surgical Treatments
  • MRI in cancer diagnosis
  • Glioma Diagnosis and Treatment
  • Advanced MRI Techniques and Applications
  • Colorectal and Anal Carcinomas
  • Colorectal Cancer Treatments and Studies
  • Neuroendocrine Tumor Research Advances
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Lung Cancer Diagnosis and Treatment
  • Advanced X-ray and CT Imaging
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Screening and Detection
  • Effects of Radiation Exposure
  • Bladder and Urothelial Cancer Treatments
  • Advances in Oncology and Radiotherapy
  • Pancreatitis Pathology and Treatment

Medical College of Wisconsin
2016-2025

Froedtert Hospital
2021-2025

Pancreatic Cancer Action Network
2023

Empowerment Program
2022

NRG Oncology
2018-2021

Valley Hospital
2021

Medical College of Wisconsin Cancer Center
2021

Icahn School of Medicine at Mount Sinai
2021

Milwaukee VA Medical Center
2017-2019

CARE Canada
2019

Purpose Conventional radiotherapy (C-RT) treatment schedules for patients with prostate cancer typically require 40 to 45 treatments that take place from > 8 9 weeks. Preclinical and clinical research suggest hypofractionation—fewer but at a higher dose per treatment—may produce similar outcomes. This trial was designed assess whether the efficacy of hypofractionated (H-RT) schedule is no worse than C-RT in men low-risk cancer. Patients Methods A total 1,115 were randomly assigned 1:1...

10.1200/jco.2016.67.0448 article EN Journal of Clinical Oncology 2016-04-05

Carbohydrate antigen 19-9 (CA19-9) is a prognostic marker for patients with pancreatic cancer (PC), but its value as treatment biomarker unclear.Although CA19-9 an established PC, it unclear how monitoring should be used to guide multimodality and what level of change in constitutes meaningful response.CA19-9 measurements at diagnosis (pretx), after completion all planned neoadjuvant therapy (preop), surgery (postop) were analyzed localized PC who had elevated (≥35 U/dL) diagnosis. Patients...

10.1097/sla.0000000000003049 article EN Annals of Surgery 2018-10-12

<h3>Importance</h3> Total neoadjuvant therapy (TNT) is often used to downstage locally advanced rectal cancer (LARC) and decrease locoregional relapse; however, more than one-third of patients develop recurrent metastatic disease. As such, novel combinations are needed. <h3>Objective</h3> To assess whether the addition pembrolizumab during after chemoradiotherapy can lead an improvement in (NAR) score compared with treatment FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) alone. <h3>Design,...

10.1001/jamaoncol.2021.1683 article EN JAMA Oncology 2021-07-01

Decipher (Decipher Biosciences Inc) is a genomic classifier (GC) developed to estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with prostate cancer.To validate GC context randomized phase 3 trial.This ancillary study used RP specimens from placebo-controlled NRG/RTOG 9601 clinical trial conducted March 1998 2003. The were centrally reviewed, and RNA was extracted highest-grade tumor available 2019 median follow-up 13 years. Clinical-grade whole...

10.1001/jamaoncol.2020.7671 article EN JAMA Oncology 2021-02-12

Changes of radiomic features over time in longitudinal images, delta radiomics, can potentially be used as a biomarker to predict treatment response. This study aims develop delta-radiomic process based on machine learning by (1) acquiring and registering (2) segmenting populating regions interest (ROIs), (3) extracting calculating their changes (delta-radiomic features, DRFs), (4) reducing feature space determining candidate DRFs showing treatment-induced changes, (5) creating outcome...

10.1038/s41698-019-0096-z article EN cc-by npj Precision Oncology 2019-10-04

BACKGROUND As systemic therapy has improved for locally advanced pancreatic cancer (LAPC), efforts to improve local control with optimal radiotherapy may be critical. Although conventionally fractionated radiation (CFRT) more recently shown a limited role in LAPC, stereotactic body (SBRT) is an emerging approach promising results. With no studies date comparing SBRT CFRT this study used the National Cancer Data Base (NCDB) evaluate these 2 modalities. METHODS NCDB, patients American Joint...

10.1002/cncr.30706 article EN Cancer 2017-05-10

BACKGROUND Mixed lineage kinase domain‐like protein (MLKL) is a necrosome component mediating programmed necrosis that may be an important determinant of cancer cell death. The goal the current study was to evaluate prognostic value MLKL expression in patients with pancreatic adenocarcinoma (PAC). METHODS Tissue from 80 collected prospectively maintained database PAC who underwent pancreaticoduodenectomy between January 2000 and October 2008. Immunohistochemistry analysis performed scored...

10.1002/cncr.28144 article EN Cancer 2013-05-29

Purpose: MR-guided Radiation Therapy (MRgRT) allows for high-precision radiotherapy under real-time MR visualization. This enables margin reduction and subsequent dose escalation which may lead to higher tumor control less toxicity. The Unity MR-linac (Elekta AB, Stockholm, Sweden) integrates a linear accelerator with 1.5T diagnostic quality MRI an online adaptive workflow. A prospective international registry was established facilitate the evidence-based implementation of into clinical...

10.3389/fonc.2020.01328 article EN cc-by Frontiers in Oncology 2020-09-07

In this report, we describe our implementation and initial clinical experience using 4D-MRI driven MR-guided online adaptive radiotherapy (MRgOART) for abdominal stereotactic body (SBRT) on the Elekta Unity MR-Linac.Eleven patients with malignancies were treated free-breathing SBRT in three to five fractions a 1.5 T MR-Linac. Online plans generated Adapt-To-Position (ATP) or Adapt-To-Shape (ATS) workflows based motion averaged mid-position images derived from pre-beam 4D-MRI. A high...

10.1016/j.ctro.2020.05.002 article EN cc-by-nc-nd Clinical and Translational Radiation Oncology 2020-05-15

The incidence of rectal cancer in patients younger than 50 years is increasing. To test the hypothesis that biology this cohort may differ, study compared survival patterns, stratifying according to National Comprehensive Cancer Network (NCCN) guideline-driven care and age.The Data Base was queried for treated with curative-intent transabdominal resections negative surgical margins stage I III between 2004 2014. Outcomes overall old or older were by subgroups based on NCCN care.A total...

10.1002/cncr.31527 article EN Cancer 2018-07-09

<h3>Importance</h3> In men with recurrent prostate cancer, addition of long-term antiandrogen therapy to salvage radiotherapy (SRT) was associated overall survival (OS) in the NRG/RTOG 9601 study. However, hormone has morbidity, and there are no validated predictive biomarkers identify which patients derive most benefit from treatment. <h3>Objective</h3> To examine role pre-SRT prostate-specific antigen (PSA) levels personalize use SRT. <h3>Interventions</h3> Men were randomized SRT plus...

10.1001/jamaoncol.2020.0109 article EN JAMA Oncology 2020-03-26

Recent data have demonstrated that in locally advanced rectal cancer (LARC), a total neoadjuvant therapy (TNT) approach improves compliance with chemotherapy and increases rates of tumor response compared to chemoradiation (CRT) alone. They further indicate the optimal sequencing TNT involves consolidation (rather than induction) optimize complete rates. Data, largely from retrospective studies, also shown patients clinical (cCR) after may be managed safely watch wait (WW) instead preemptive...

10.1186/s12885-024-12529-7 article EN cc-by BMC Cancer 2024-07-26

Mice treated p.o. with 5% dextran sodium sulfate develop a mild to moderate colitis characterized by focal areas of inflammation and crypt abscesses. Immunohistological analysis colons from sulfate-treated mice revealed an increased expression intercellular adhesion molecule 1 (ICAM-1) infiltration lymphocyte function antigen 1-positive cells. A murine-specific antisense oligonucleotide, ISIS 3082, was used determine the role ICAM-1 in development colitis. Prophylactic treatment 3082 reduced...

10.1016/s0022-3565(24)36471-7 article EN Journal of Pharmacology and Experimental Therapeutics 1997-02-01
Coming Soon ...